Studying Harms Is Key to Improving Psychedelic-Assisted Therapy-Participants Call for Changes to Research Landscape

JAMA Psychiatry. 2023 May 1;80(5):411-412. doi: 10.1001/jamapsychiatry.2023.0099.

Authors

Sarah McNamee¹, Nese Devenot², Meaghan Buisson³

Affiliations

¹ School of Social Work, McGill University, Montreal, Quebec, Canada.
² Institute for Research in Sensing, University of Cincinnati, Cincinnati, Ohio.
³ Independent researcher, Winnipeg, Manitoba, Canada.

PMID: 36988924
DOI: 10.1001/jamapsychiatry.2023.0099

No abstract available

Plain language summary

This Viewpoint discusses serious adverse events linked to interactions between therapists and patients in trials of psychedelic-assisted therapy.

MeSH terms

Hallucinogens* / adverse effects
Humans
Psilocybin
Psychotherapy
Research

Substances

Hallucinogens
Psilocybin